Blokhin Cancer Research Center

Moskva, Moscow Oblast 115478

0 studies enrolling now · 2 studies all time

What they study most

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer, Neoplasm Metastasis

Studies at this site

• A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) — Running, not enrolling
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies — Running, not enrolling